03:50 PM EST - Lorus Therapeutics Inc. : announced the enrollment of the first cancer patient in a Phase I clinical study evaluating its small molecule anticancer drug candidate LOR-253. Lorus Therapeutics Inc.
shares T.LOR are trading down $0.02 at $1.01.
